With the 5-gene prostate cancer metastasis signature panel comprised of U2AF2, RUVBL1, STMN1, HDGF, and FABP4, we further assessed the power of prediction of this gene signature panel in two different, independent public patient datasets (Grasso CS, Nature, 2012; Varambally S CS, Cancer Cell, 2005) [20, 21]. This evidence concerns the gene FABP4 and Familial prostate cancer.